

Amarantus Bioscience Holdings, Inc.

Form 3

September 04, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Â COMMISSIONG GERALD

(Last)

(First)

(Middle)

C/O JANSSEN LABS  
@QB3,Â 953 INDIANA  
STREET

(Street)

SAN  
FRANCISCO,Â CAÂ 94107

(City)

(State)

(Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)

08/02/2013

3. Issuer Name and Ticker or Trading Symbol

Amarantus Bioscience Holdings, Inc. [AMBS]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner☒ Officer ☐ Other (specify below)

CEO

6. Individual or Joint/Group

Filing(Check Applicable Line)

☒ Form filed by One Reporting Person☐ Form filed by More than One Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Common Stock

7,889,565

D

Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of Derivative

5. Ownership Form of Derivative Security:

6. Nature of Indirect Beneficial Ownership (Instr. 5)

# Edgar Filing: Amarantus Bioscience Holdings, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Series C Convertible Preferred Stock	04/03/2013	Â (1)	Common Stock	175,000	\$ (2)	D	Â
Series C Convertible Preferred Stock	11/01/2013	Â (1)	Common Stock	175,000	\$ (2)	D	Â
Option to Purchase Common Stock	09/25/2011	04/10/2021	Common Stock	269,329	\$ 0.0237	D	Â
Warrants to Purchase Common Stock	09/26/2013	09/26/2016	Common Stock	138,889	\$ 0.06	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
COMMISSIONG GERALD C/O JANSSEN LABS @QB3 953 INDIANA STREET SAN FRANCISCO,Â CAAÂ 94107	Â	Â	Â CEO	Â

## Signatures

/s/ Gerald  
Commissiong 09/03/2014

\_\_Signature of  
Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Not applicable.
- (2) Each share of Series C Convertible Preferred Stock is convertible into 1 shares of the Issuer's common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.